A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies-Reference-Cited by-同舟云学术

A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies

Published:2013-03-07 Issue:5 Volume:71 Page:1273-1285
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Chow Laura Q. M.,Jonker Derek I.,Dy Grace K.,Nicholas Garth,Fortin Catherine,Patricia Daniel,Adjei Alex A.,Belani Chandra P.,Gupta Ashok,Park Jong-Soon,Zhang Steven,Sbar Eric I.,Laurie Scott A.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-013-2126-9.pdf

Reference46 articles.

1. Schwartz GN, Pendyala L, Kindler H, Meropol N, Perez R, Raghavan D et al (1998) The clinical development of paclitaxel and the paclitaxel/carboplatin combination. Eur J Cancer 34:1543–1548

2. Chu Q, Vincent M, Logan D, Mackay JA, Evans WK (2005) Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer (Amsterdam, Netherlands) 50:355–374

3. Ozols RF (2002) Update on the management of ovarian cancer. Cancer J (Sudbury, Mass) 8(Suppl 1):S22–S30

4. Marathe P, Tang Y, Sleczka B, Rodrigues D, Gavai A, Wong T et al (2010) Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci 99:3579–3593

5. Seymour L (2003) Epidermal growth factor receptor inhibitors: an update on their development as cancer therapeutics. Curr Opin Investig Drugs 4:658–666

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer;Expert Opinion on Investigational Drugs;2016-02-29

2. Development of EGFR Family Small Molecule Inhibitors for Anticancer Intervention: An Overview of Approved Drugs and Clinical Candidates;Current Medicinal Chemistry;2014-11-12

3. Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2;Future Medicinal Chemistry;2014-10

4. Kinase Inhibitors in Cancer;Reference Module in Chemistry, Molecular Sciences and Chemical Engineering;2014